PTGS2 and osteoporosis: In addition, the potential core targets of FZD in the treatment of osteoporosis were selected using CytoNCA, which included IFNG, HMOX1, CAT, AKT1, PTGS2, ESR1, PPARG, CASP3, IL1B, CYP1A1, NR3C1, and VCAM1 (Fig. 3B).